Keith L. Lui
Corporate Officer/Principal bei DURECT CORPORATION
Ursprung des Netzwerks ersten Grades von Keith L. Lui
| Einheit | Art der Einheit | Industrie | |
|---|---|---|---|
| Public Company | Pharmaceuticals: Major | 19 | |
Versartis, Inc.
 Versartis, Inc. Pharmaceuticals: MajorHealth Technology Versartis, Inc. is an endocrine-focused biopharmaceutical company, which engages in the research and development of pharmaceutical products. Its portfolio includes Somavartan and XTEN TEchnology which target the endocrine disorders and growth hormone deficiencies. The company was founded by Jeffrey L. Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman on December 10, 2008 and is headquartered in Menlo Park, CA.
9
| Extinct | Pharmaceuticals: Major | 9 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Keith L. Lui
| Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
|---|---|---|---|
| PFIZER, INC. | Pharmaceuticals: Major | Sales & Marketing General Counsel Corporate Officer/Principal | |
| ALZA CORPORATION | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Director of Finance/CFO Director/Board Member | |
| University of Denver | College/University | Undergraduate Degree Graduate Degree | |
| University of California, Davis | College/University | Doctorate Degree Undergraduate Degree | |
| Harvard Business School | College/University | Masters Business Admin Corporate Officer/Principal | |
NextWave Pharmaceuticals, Inc.
 NextWave Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology NextWave Pharmaceuticals, Inc. operates as a pharmaceutical company which focuses on the development and commercialization of products for the treatment of attention deficit hyperactivity disorder. The company was founded by Mahendra G. Shah on September 25, 2006 and is headquartered in New York, NY. | Pharmaceuticals: Major | Sales & Marketing Compliance Officer | |
Ilypsa, Inc.
 Ilypsa, Inc. BiotechnologyHealth Technology Ilypsa, Inc. operates a biopharmaceutical firm. It develops renal care pharmaceutical products. The company was founded on March 6, 2003 and is headquartered in Thousand Oaks, CA. | Biotechnology | Chief Executive Officer General Counsel | |
| NEKTAR THERAPEUTICS | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal | |
| University of Virginia | College/University | Undergraduate Degree Undergraduate Degree | |
| PDL BIOPHARMA, INC. | Biotechnology | President Director of Finance/CFO | |
| University of California, Berkeley | College/University | Undergraduate Degree Doctorate Degree | |
BaroFold, Inc.
 BaroFold, Inc. Pharmaceuticals: MajorHealth Technology BaroFold, Inc. develops and commercializes protein therapeutics. Its services include protein refolding, protein analytical and aggregate characterization, formulation stability and immunogenicity studies, and microbial expression. The company was founded by Matthew Seefeldt, Matthew Brewer, John F. Carpenter, Ted Randolph, Timothy C. Rodell, and Lyndal K. Hesterberg in 2009 and is headquartered in Aurora, CO. | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal | |
| ARAVIVE, INC. | Biotechnology | Director/Board Member Corporate Officer/Principal | |
ProFibrix BV
 ProFibrix BV BiotechnologyHealth Technology ProFibrix BV develops and markets products for the hemostasis and regenerative medicine markets. Its product in pipeline, ProFibrix, is a hemostatic agent for mild to moderate surgical bleeding. The firm operates through its offices located in Leiden and Seattle. It is a subsidiary of The Medicines Company. The company was founded in 2004 by Jaap Koopman and is headquartered in Leiden, the Netherlands. | Biotechnology | Director/Board Member | |
7TM A/S
 7TM A/S Pharmaceuticals: MajorHealth Technology 7TM A/S performs research and development within biotechnology. It engages in clinical development of drugs focusing on obesity and gastrointestinal diseases. The company was founded by Thue Walter Schwartz, Anders Fink Vadsholt, Mette Kirstine Agger, Christian Ellebæk Elling, and Peter Moldt on January 1, 2000 and is headquartered in Hørsholm, Denmark. | Pharmaceuticals: Major | Director/Board Member | |
| MOLECULAR PARTNERS AG | Biotechnology | Director/Board Member | |
Hamilton Pharmaceuticals, Inc.
 Hamilton Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Hamilton Pharmaceuticals, Inc. develops and supplies pharmaceuticals. It also develops and commercializes novel medical treatments for central nervous system disease. The company was founded in April 2004 and is headquartered in Washington, DC. | Miscellaneous Commercial Services | Director/Board Member | |
Genebiotech Co., Ltd.
 Genebiotech Co., Ltd. BiotechnologyHealth Technology Part of Helixmith Co., Ltd., Genebiotech Co., Ltd. is a South Korean company that develops gene and cell-based machines. The company is based in Seoul, South Korea. Genebiotech Co. was acquired by Helixmith Co., Ltd. on May 30, 2006. | Biotechnology | Director/Board Member | |
| Index Ventures (UK) LLP | Investment Managers | Private Equity Investor | |
NormOxys, Inc.
 NormOxys, Inc. Pharmaceuticals: MajorHealth Technology NormOxys, Inc. develops small-molecule therapeutics for the treatment of cancer. Its major product is OXY111A. The company was founded by Conrad J Bletzer, Jr. Claude Nicoalu, Jean-Mearie Lehn, Gay Goodman, Ruth Greferath and Roscoe Brady in 2004 and is headquartered in Brighton, MA. | Pharmaceuticals: Major | Director/Board Member | |
Sequenta, Inc.
 Sequenta, Inc. BiotechnologyHealth Technology Sequenta, Inc. operates as a biotech company which discovers and develops clinical diagnostics based on immune system status. It develops molecular diagnostic assays based on a sequencing approach to the profiling of T and B cell receptor repertoires. The firm also provides sequencing-based test for minimal residual disease for leukemia and lymphoma. The company was founded by Thomas D. Willis and Malek Faham in 2007 and is headquartered in South San Francisco, CA. | Biotechnology | Director/Board Member | |
Inexia Ltd.
 Inexia Ltd. Medical SpecialtiesHealth Technology Inexia Ltd. develops intranasal orexin positive modulators for the treatment of narcolepsy. The company is headquartered in London, the United Kingdom. | Medical Specialties | Director/Board Member | |
UltraHuman Ltd.
 UltraHuman Ltd. Miscellaneous Commercial ServicesCommercial Services UltraHuman Ltd. engages in research and experimental development on biotechnology. The company is headquartered in Sandwich, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member | |
Xenikos BV
 Xenikos BV Medical SpecialtiesHealth Technology Xenikos BV focuses on the development of immunotherapies for the treatment of patients suffering from immune diseases. It is developing a combination of two toxin-loaded anti-T-cell antibodies, T-Guard, as a therapeutic tool for resetting the body's immune system in T-cell mediated diseases. The company was founded by Ypek van Oosterhout in September 2009 and is headquartered in Nijmegen, the Netherlands. | Medical Specialties | Director/Board Member | |
Levicept Ltd.
 Levicept Ltd. Pharmaceuticals: GenericHealth Technology Levicept Ltd. develops a biological therapy for the treatment of osteoarthritis and chronic pain. Its treatments include p75NTR-Fc and LEVI-04. The company was founded by Simon Lempriere Westbrook on August 23, 2012 and is headquartered in Sandwich, the United Kingdom. | Pharmaceuticals: Generic | Director/Board Member | |
Synox Therapeutics Ltd.
 Synox Therapeutics Ltd. BiotechnologyHealth Technology Synox Therapeutics Ltd. a clinical stage biopharmaceutical company. The company is headquartered in Dublin, Ireland. | Biotechnology | Director/Board Member | |
Rivus Pharmaceuticals, Inc.
 Rivus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Rivus Pharmaceuticals, Inc. is a company dedicated to improving metabolic health by advancing a new class of medicines called controlled metabolic accelerators (CMAs). The company is based in Charlottesville, VA. Jayson Donald Alexander Dallas has been the CEO of the company since 2021. The company is a leader in mitochondrial biology and is developing a new class of medicines to address a primary driver of cardio-metabolic disease: obesity. Rivus' lead CMA is the investigational small molecule HU6 in development to treat obesity and associated metabolic diseases, including heart failure with preserved ejection fraction (HFpEF), metabolic dysfunction-associated steatotic liver disease (MASLD)/metabolic dysfunction-associated steatohepatitis (MASH), and type 2 diabetes. | Pharmaceuticals: Major | Director/Board Member | |
SDS Therapeutics Ltd.
 SDS Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services SDS Therapeutics Ltd. is a British biotechnology company founded in 2020 that provides research and development services. The company is based in Cambridge, UK. | Miscellaneous Commercial Services | Director/Board Member | |
| CENTESSA PHARMACEUTICALS PLC | Pharmaceuticals: Major | Chairman | |
Orexia Therapeutics Ltd.
 Orexia Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Orexia Ltd. develop orally administered orexin positive modulators for the treatment of neurological diseases. The company was founded on October 5, 2018 and is headquartered in London, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member | |
Egalet Ltd.
 Egalet Ltd. Pharmaceuticals: MajorHealth Technology Egalet Ltd. engages in manufacturing of basic pharmaceutical products. It focuses on the commercialization and development of abuse resistant formulations of opioids and other pain care drugs. The company was founded on July 15, 2010 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
| ZYLA LIFE SCIENCES | Pharmaceuticals: Major | Director/Board Member | |
Medicxi Ventures (Jersey) Ltd.
 Medicxi Ventures (Jersey) Ltd. Investment ManagersFinance Medicxi Ventures (Jersey) Ltd. (Medicxi) is an independent venture capital firm founded in 2016 by Francesco de Rubertis, Michèle Ollier, and Kevin S. Johnson. The firm is headquartered in London. | Investment Managers | Founder | |
| ADDEX THERAPEUTICS LTD | Pharmaceuticals: Major | Director/Board Member | |
| GENMAB A/S | Pharmaceuticals: Major | Director/Board Member | |
| MINERVA NEUROSCIENCES, INC. | Pharmaceuticals: Major | Director/Board Member | |
Egalet A/S
 Egalet A/S Pharmaceuticals: MajorHealth Technology Egalet A/S operates as a specialty pharmaceuticals company. It develops opioid formulations for pain management based on abuse deterrent prolonged release erosion matrix technology in Denmark. The company develops prolonged and delayed release therapeutics for chronic pain management, including Parvulet, a delivery platform for facilitating dispensing of oral doses to pediatric and geriatric patient segments; and Egalet morphine. The company was founded by Jan Quistgaard in 1995 and is headquartered in Vaerloese, Denmark. | Pharmaceuticals: Major | Director/Board Member | |
Cellzome Ltd.
 Cellzome Ltd. Pharmaceuticals: MajorHealth Technology Cellzome Ltd. engages in the research, development, and manufacture of pharmaceutical products. It provides kinase-targeted drugs to treat inflammatory diseases. The company was founded by Gitte Neubauer on December 22, 2003 and is headquartered in Middlesex, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
Shorla Pharma Ltd.
 Shorla Pharma Ltd. Pharmaceuticals: MajorHealth Technology Shorla Pharma Ltd. manufactures drugs in the oncology space for women’s and pediatric cancers. Its products include SH-111. The company was founded by Sharon Cunningham and Orlaith Ryan in 2018 and is headquartered in Clonmel, Ireland. | Pharmaceuticals: Major | Director/Board Member | |
| University of Pavia | College/University | Undergraduate Degree | |
Amphioxus Cell Technologies, Inc.
 Amphioxus Cell Technologies, Inc. BiotechnologyHealth Technology Amphioxus Cell Technologies, Inc. manufactures biological drug discovery products. It develops human liver based tools from liver biology to drug disposition, viral hepatitis, plasma proteins, and cell culture models. The company was founded by James H. Kelly and Norman L. Sussman in 1995 and is headquartered in Houston, TX. | Biotechnology | Founder |
Statistik
International
| Vereinigte Staaten | 26 |
| Vereinigtes Königreich | 12 |
| Schweiz | 5 |
| Niederlande | 4 |
| Dänemark | 4 |
Sektoral
| Health Technology | 37 |
| Consumer Services | 7 |
| Commercial Services | 7 |
| Finance | 3 |
Operativ
| Director/Board Member | 146 |
| Corporate Officer/Principal | 74 |
| Independent Dir/Board Member | 40 |
| Chairman | 24 |
| President | 24 |
Am stärksten vernetzte Beziehungen
| Insiders | |
|---|---|
| Jon Saxe | 43 |
| Francesco de Rubertis | 36 |
| R. Greer | 23 |
| Jeffrey L. Cleland | 21 |
| Mohammad Azab | 21 |
| Gail Maderis | 20 |
| Peter García | 19 |
| Gail Farfel | 15 |
| Eric Dobmeier | 14 |
| Tracy Woody | 13 |
| Judith Robertson | 12 |
| David Hoffmann | 10 |
| Shane Ward | 10 |
| Mike Burdick | 9 |
| Norman Sussman | 9 |
- Börse
- Insiders
- Keith L. Lui
- Unternehmensverbindungen
